Australian radiopharmaceutical company Cyclopharm (ASX:CYC) has achieved a significant milestone in its US expansion, with Lucile Packard Children’s Hospital Stanford set to implement Technegas for paediatric lung imaging.

Dimerix (ASX:DXB) has found itself at the centre of a significant global rare-disease transaction, following BioMarin Pharmaceutical’s US$4.8 billion acquisition of Amicus Therapeutics, the Australian company’s U.S. commercial licensing partner.

Clarity Pharmaceuticals (ASX:CU6) has taken a step toward regulatory approval of its diagnostic imaging agent, announcing it will commence a pivotal Phase 3 trial of Cu-64 SARTATE in patients with neuroendocrine tumours following positive guidance from the U.S. Food and Drug Administration.

Telix Pharmaceuticals (ASX:TLX) has delivered a significant advance in its global precision medicine strategy, announcing positive topline results from a pivotal Phase 3 registration study of TLX591-CDx (ILLUCCIX) in Chinese patients with prostate cancer.

INOVIQ (ASX:IIQ) has reported preclinical evidence supporting the potential of its chimeric antigen receptor exosome technology as a next-generation cancer therapeutic.

Neuren Pharmaceuticals (ASX:NEU) has reached a regulatory milestone with Health Canada approving its Clinical Trial Application for the Koala Phase 3 clinical trial of NNZ-2591, a drug candidate under development for Phelan-McDermid syndrome.

A new antimalarial drug candidate developed through a long-running collaboration between Melbourne’s WEHI and MSD is showing promise in the fight against malaria, particularly as resistance to existing treatments continues to spread.

Australian medtech company Ferronova has raised a further $6 million to support the commercialisation of its image-guided cancer surgery technology.

Actinogen Medical (ASX:ACW) has hit a significant milestone in its push to bring a new oral Alzheimer’s therapy to market, completing enrolment in its pivotal XanaMIA trial and confirming November 2026 for topline results.

Island Pharmaceuticals (ASX:ILA) has taken a step forward in the development of its antiviral candidate galidesivir, securing a strategic partnership with the Texas Biomedical Research Institute, one of the world’s most advanced infectious disease centres and a critical player in high-containment pathogen research.

Cleo Diagnostics (ASX:COV) has secured $5 million in capital to support its expansion into the United States and speed the development of a new mass screening test for ovarian cancer, in a raise that attracted strong backing from institutional and high-net-worth investors.

OncoSil Medical (ASX:OSL) has marked a significant milestone in its manufacturing strategy, announcing the successful completion of the first 'hot' production test run at its new Sydney facility.

MTPConnect has launched applications for its 2026 Pathway to Market – Medtech Capability Uplift Program, a Victorian initiative designed to help local medtech manufacturers secure procurement opportunities with hospitals and health services.

Radiopharm Theranostics (ASX:RAD) has announced encouraging interim results from its U.S.-based Phase 2b clinical imaging trial of RAD 101, reporting that 92 per cent of evaluable patients achieved concordance between RAD 101 PET imaging and MRI, the study’s primary endpoint.

Cynata Therapeutics (ASX:CYP) has reached a clinical milestone, completing patient enrolment in its Phase 2 trial of CYP-001, an investigational stem-cell therapy for acute graft-versus-host disease

Dimerix (ASX:DXB) has reached a significant milestone in its late-stage clinical program, announcing that its global ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis has now completed recruitment and dosing of its target 286 adult patients.

Algorae Pharmaceuticals (ASX:1AI) has taken a significant step forward in AI-enabled drug discovery, announcing the completion of a sweeping set of in silico synergy predictions generated by its upgraded platform, AlgoraeOS v2.